Background
==========

The European LeukemiaNet \[[@B1]\], European Society of Medical Oncology \[[@B2]\], and National Comprehensive Cancer Network (US) \[[@B3]\] recently indicated that management of patients aged ≥60 years with acute myeloid leukemia (AML) should be guided by performance status and presence of comorbidities. Until recently, treatment approaches had proven difficult in older patients. However, international treatment guidelines for AML now include low-intensity cytarabine, 5-azacytidine, and decitabine as therapeutic options \[[@B1],[@B3]\].

Decitabine, a hypomethylating agent, was approved by the European Medicines Agency in late 2012 for treatment of patients aged ≥65 years with newly diagnosed de novo or secondary AML \[[@B4]\]. Decitabine appears to have direct cytotoxic effects and is believed to affect cellular differentiation and apoptosis. In the US, it is indicated for treatment of previously treated and untreated de novo and secondary myelodysplastic syndrome (MDS) of all French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups \[[@B5]\]. In patients with MDS \[[@B6]\], chronic myelomonocytic leukemia \[[@B6]\], or AML, intravenous (IV) decitabine 20 mg/m^2^ administered daily for 5 consecutive days every 4 weeks was well tolerated \[[@B7]\].

A recently reported phase 3 trial in older patients (≥65 years) with newly diagnosed AML and poor- or intermediate-risk cytogenetics compared the efficacy and safety of decitabine with patient's treatment choice (TC), upon physician's advice, of supportive care (SC) or cytarabine \[[@B8]\]. The study had a planned clinical cutoff date of October 28, 2009; 396 deaths had occurred. The primary efficacy analysis (October 2009) showed a nonsignificant trend toward increased median overall survival (OS) with decitabine (7.7 months; 95% confidence interval \[CI\]: 6.2--9.2 months) versus TC (5.0 months; 95% CI: 4.3--6.3 months), with an estimated hazard ratio (HR) of 0.85 (p = 0.108). In a post hoc analysis using mature data (clinical cutoff October 29, 2010) \[[@B8]\], 446 deaths had occurred. Median OS was the same as that in the 2009 analysis, but with improved HR (0.82; 95% CI: 0.68--0.99; nominal p = 0.037) with decitabine. At the 2009 cutoff, significantly improved remission rates were observed with decitabine versus TC (complete response \[CR\] or CR with incomplete platelet recovery \[CRp\], 17.8% vs 7.8%, respectively; p = 0.001), and decitabine was well tolerated.

Using mature (2010) data from the phase 3 trial \[[@B8]\], this multivariate analysis aimed to identify potential predictors of survival and response in this older population with AML. Prespecified analyses of response and survival by subgroups are also reported.

Methods
=======

Patients and study design
-------------------------

Patients aged ≥65 years with newly diagnosed, histologically confirmed de novo or secondary AML (≥20% blasts), poor- or intermediate-risk cytogenetics (Southwest Oncology Group categorization \[[@B9]\]), and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0--2 were eligible. Excluded patients had t(15;17), t(8;21), or inv(16) karyotype abnormalities. Complete protocol details were previously reported \[[@B8]\].

This study, conducted in 15 countries, was approved by institutional review boards or independent ethics committees and conducted in accordance with the Declaration of Helsinki. All patients provided written, informed consent.

Patients in this randomized, open-label, phase 3 trial indicated, with physician's advice, their preferred TC of SC or once-daily cytarabine 20 mg/m^2^ subcutaneously for 10 consecutive days every 4 weeks. Patients were randomized 1:1 to receive decitabine or TC, stratified by age, cytogenetic risk, and ECOG PS. Once-daily decitabine 20 mg/m^2^ was administered as a 1-hour IV infusion for 5 consecutive days every 4 weeks. Treatment continued until relapse or progressive disease (PD), death, unacceptable toxicity, lack of clinical benefit, intercurrent illness preventing treatment, or patient/physician request.

The primary objective was to compare OS (from randomization to death) in patients receiving decitabine versus TC. Secondary objectives were to compare response rates, including CR and CRp, based on bone marrow biopsies and aspirates. Patients were followed monthly for 2 years post-randomization, then every 2 months for 3 years for OS and PD until death or loss to follow-up.

Statistical analysis
--------------------

The primary OS analysis was based on the 2009 clinical cutoff date \[[@B8]\]. To provide additional data, a post hoc analysis evaluated mature 2010 survival data \[[@B8]\]. Mature data were utilized for this multivariate analysis. At the 2010 clinical cutoff, \>90% of events were recorded.

A multivariate Cox proportional hazards model was used to investigate the effects of the following baseline characteristics on OS: gender, age (\<70, 70 to \<75, and ≥75 years), baseline cytogenetic risk (intermediate vs poor), AML type (de novo vs secondary), baseline ECOG PS (0/1 vs 2), region (North America/Australia, Western Europe, Eastern Europe, or Asia), baseline bone marrow blasts (\>50% vs ≤50%), baseline platelet counts (at each unit of 100 ×10^9^/L), and baseline white blood cell (WBC) counts (at each unit of 25 ×10^9^/L). These potential prognostic factors were evaluated all at once and p values determined without adjustment for multiple testing.

For probability of achieving CR or CRp, a logistic regression model was used to investigate effects of the same demographic and baseline characteristics. Again, these factors were evaluated simultaneously and p values determined without adjustment for multiple testing.

Prespecified subgroup analyses were additionally performed based on mature data to compare OS between decitabine and TC using the Cox regression model stratified by age, cytogenetic risk, and ECOG PS (same model used for the study's primary OS analysis) \[[@B8]\]. Subgroups included those with baseline bone marrow blasts ≥20% and ≤30% versus \>30%; de novo versus secondary AML; intermediate-risk versus poor-risk cytogenetics; ages \<70, 70--74, and ≥75 years; and ECOG PS of 0--1 versus 2. Regional subgroups were also compared. The subanalysis for response (CR + CRp) was performed in the same subgroups, using 2-sided Fisher's exact test (same method used for the study's secondary responder analysis) \[[@B8]\].

The phase 3 study was registered with ClinicalTrials.gov with identifier NCT00260832.

Results
=======

Patients
--------

Between January 2006 and April 2009, 485 patients were randomized at 65 sites. The efficacy population comprised 242 decitabine recipients and 243 TC recipients (cytarabine, n = 215; SC, n = 28; Figure [1](#F1){ref-type="fig"}). Baseline clinical characteristics and patient demographics were similar between treatment groups (Table [1](#T1){ref-type="table"}) and reflected a high-risk population \[[@B8]\]. Approximately 71% of patients were aged ≥70 years, with secondary AML in 35.3%, poor cytogenetic risk AML in 36.0%, and ECOG PS of 2 in 25.8% of patients; median baseline bone marrow blasts were 46.0%.

![**Flow diagram for phase 3 study.** Reprinted with permission from Kantarjian H, et al. *J Clin Oncol* 2012 \[[@B8]\].](1471-2407-14-69-1){#F1}

###### 

**Patient demographics and baseline clinical characteristics**\[[@B8]\]

  **Parameter**                                    **Total TC (n = 243)**   **Decitabine (n = 242)**
  ----------------------------------------------- ------------------------ --------------------------
  Median age, years (range)                          73.0 (64.0--91.0)         73.0 (64.0--89.0)
   \<70 years                                            70 (28.8)                 71 (29.3)
   70--74 years                                          74 (30.5)                 76 (31.4)
   ≥75 years                                             99 (40.8)                 95 (39.3)
  Sex, n (%)                                                               
   Female                                                92 (37.9)                 105 (43.4)
   Male                                                  151 (62.1)                137 (56.6)
  Median BSA, m^2^ (range)                            1.80 (1.3--2.7)           1.82 (1.4--2.6)
  Median time since AML diagnosis, days (range)       15.0 (0--398.0)          14.0 (3.0--346.0)
  Type of AML, n (%)                                                       
   De novo                                               157 (64.6)                155 (64.0)
   Secondary                                             84 (34.6)                 87 (36.0)
  Bone marrow blasts, n (%)                                                
   \<20%                                                  8 (3.3)                   4 (1.7)
   20%--30%                                              58 (24.1)                 65 (27.0)
   \>30%--50%                                            74 (30.7)                 67 (27.8)
   \>50%                                                 101 (41.9)                105 (43.7)
  ECOG PS, n (%)                                                           
   0 or 1                                                178 (73.2)                182 (75.3)
   2                                                     65 (26.7)                 60 (24.8)
  Cytogenetics, n (%)                                                      
   Intermediate risk                                     154 (63.6)                152 (63.1)
   Poor risk                                             87 (36.0)                 87 (36.1)
  Median hemoglobin, g/dL (range)                     9.4 (5.0--12.6)           9.3 (5.2--15.0)
  Platelets, n                                              213                       225
   Median, 10^9^/L (range)                           50.00 (6.0--490.0)        58.00 (6.0--487.0)
  White blood cells, n                                      236                       237
   Median, 10^9^/L (range)                            3.69 (0.5--80.9)         3.10 (0.3--127.0)

AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TC, treatment choice, with physician's advice.

Considering enrollment by region and country (Table [2](#T2){ref-type="table"}), the largest proportion of patients in each treatment group was from Eastern Europe (46.5%, TC; 45.0%, decitabine).

###### 

**Trial enrollment by region and country**\[[@B8]\]

  **Region**                     **Country**           **TC (n = 243)**   **Decitabine (n = 242)**
  ------------------------------ -------------------- ------------------ --------------------------
  **Eastern Europe**                                      113 (46.5)             109 (45.0)
                                 Poland                   47 (19.3)              41 (16.9)
                                 Russian Federation       29 (11.9)              28 (11.6)
                                 Czech Republic            23 (9.5)               24 (9.9)
                                 Serbia                    10 (4.1)               12 (5.0)
                                 Hungary                   3 (1.2)                4 (1.7)
                                 Romania                   1 (0.4)                0 (0.0)
  **North America/ Australia**                            69 (28.4)              51 (21.1)
                                 United States            27 (11.1)               21 (8.7)
                                 Australia                 22 (9.1)               16 (6.6)
                                 Canada                    20 (8.2)               14 (5.8)
  **Western Europe**                                      34 (14.0)              51 (21.1)
                                 France                    24 (9.9)              31 (12.8)
                                 Spain                     10 (4.1)               20 (8.3)
  **Asia**                                                27 (11.1)              31 (12.8)
                                 Taiwan                   27 (11.1)              31 (12.8)

Percentages were calculated using the number of patients in each group as the denominator.

SC, supportive care; TC, patient\'s choice of treatment with physician\'s advice.

Multivariate analysis
---------------------

After adjustment for potential prognostic factors, the HR for treatment effect on OS based on mature data was 0.799 (95% CI: 0.653--0.978), favoring decitabine (Table [3](#T3){ref-type="table"}). Patient characteristics appearing to negatively influence OS at the 0.05 level included advanced age, poorer baseline ECOG PS, poor cytogenetic risk, higher bone marrow blast counts, low baseline platelet counts, and higher WBC counts. Geographically, being in the Western European subgroup was predictive of a longer median OS.

###### 

Overall survival: multivariate proportional hazard analysis

  **Variable**                                       **Hazard ratio**     **95% CI**     **P value**
  ------------------------------------------------- ------------------ ---------------- -------------
  Treatment: decitabine vs TC                             0.799         (0.653--0.978)     0.0296
  Sex: male vs female                                     1.125         (0.912--1.388)     0.2703
  Age group                                                                                    
   70--74 vs \<70 years                                   1.311         (1.004--1.711)     0.0468
   ≥75 vs \<70 years                                      1.560         (1.198--2.032)     0.0010
  Baseline cytogenetic risk: intermediate vs poor         0.699         (0.565--0.865)     0.0010
  Type of AML: de novo vs secondary                       1.110         (0.893--1.380)     0.3452
  Baseline ECOG PS: 0 or 1 vs 2                           0.771         (0.607--0.978)     0.0321
  Geographic region \[[@B8]\]                                                                  
   Eastern Europe vs North America/Australia              1.118         (0.849--1.473)     0.4263
   Western Europe vs North America/Australia              0.727         (0.523--1.010)     0.0572
   Asia vs North America/Australia                        1.047         (0.728--1.505)     0.8052
   Western Europe vs Eastern Europe                       0.650         (0.482--0.877)     0.0048
   Western Europe vs Asia                                 0.694         (0.472--1.021)     0.0637
  Baseline bone marrow blast: \>50% vs ≤50%               1.355         (1.099--1.672)     0.0045
  Baseline platelets (10^9^/L)^a^                         0.775         (0.663--0.907)     0.0015
  Baseline WBC (10^9^/L)^b^                               1.256         (1.045--1.509)     0.0151

AML, acute myeloid leukemia; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TC, patient\'s choice of treatment with physician\'s advice; WBC, white blood cell counts.

^a^Hazard ratio less than 1 indicates lower risk associated with each additional 100 × 10^9^/L in baseline platelet counts.

^b^Hazard ratio greater than 1 indicates higher risk associated with each additional 25 × 10^9^/L in baseline WBC counts.

After adjustment for the same set of potentially prognostic factors in the logistic regression analysis for response (CR + CRp), an advantage was noted for decitabine over TC in response rate (odds ratio \[OR\] 2.751 \[95% CI: 1.487--5.091; p = 0.001). The only patient characteristic significantly influencing response rate was sex (male vs female, OR 0.551 \[95% CI: 0.304--0.998\]; p = 0.049).

Subgroup analyses
-----------------

Prespecified analyses of subgroups were performed for OS and response (CR + CRp) using 2010 mature data. In general, OS results were consistent with those using 2009 data \[[@B8]\], favoring treatment with decitabine with 3 exceptions. In the mature data set, the treatment effect on OS in the Western European subgroup favored TC, which was markedly different from the treatment effect seen in the overall population, which favored decitabine. Similarly, in the subgroup of patients with baseline bone marrow blasts of 20% to 30%, the treatment effect on OS favored TC, but favored decitabine in the overall population. Finally, for patients aged \<70 years, HR was close to unity, with neither treatment favored. Overall survival data for these subsets were reported in detail elsewhere \[[@B8]\].

In the analysis of response rates, all subgroups favored decitabine (Figure [2](#F2){ref-type="fig"}).

![**Subanalyses of patients with response to either decitabine or treatment choice (complete remission or complete remission with incomplete platelet recovery).** P values were based on 2-sided Fisher's exact test and stratified by age, cytogenetic risk, and Eastern Cooperative Oncology Group Performance Status. AML, acute myeloid leukemia; Aus., Australia; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; Med, median (months); NE, not estimable; OR, odds ratio; Resp, responder; TC, patient's choice of treatment with physician's advice.](1471-2407-14-69-2){#F2}

### Age

In patients aged \<70 years, a slightly higher proportion of patients received subsequent treatment (ie, after the trial ended) with induction chemotherapy in the TC arm (21.4%) than in the decitabine arm (16.9%), and 7.1% of patients received a subsequent hypomethylating agent in the TC arm compared with no patients in the decitabine arm. In patients aged ≥70 years, a smaller proportion of patients received subsequent induction chemotherapy (6.9%, TC arm; 8.2%, decitabine arm), while 9.8% of patients in the TC arm and 2.3% in the decitabine arm subsequently received a hypomethylating agent. When analysis of OS in the age subgroups was censored for subsequent disease-modifying therapy, an HR favoring decitabine was observed for all age groups (HR = 0.73, age ≥75 years; HR = 0.80, age 70--74 years; and HR = 0.97, age \<70 years).

### Type of acute myeloid leukemia

Although AML type was not a stratification factor, the numbers of patients with de novo or secondary AML were well balanced across treatment arms, with approximately two thirds of patients having de novo AML. Response to decitabine was observed in both subgroups (Figure [2](#F2){ref-type="fig"}), with the greater proportion of responders in the larger de novo subgroup.

### Baseline bone marrow count

Randomization was not stratified according to baseline bone marrow blast count, but counts were balanced between treatment arms: most patients (72%) had a blast count \>30%, while 43% had a blast count \>50%. Median blasts were 45.0% (range: 0--100) in the TC arm and 46.6% (range: 3--100) in the decitabine arm. For the subgroup of patients with 20% to 30% blasts, a lower proportion of patients had an ECOG PS of 0 in the decitabine arm compared with the TC arm (20% vs 31%, respectively), and a higher percentage of patients in the decitabine arm compared with the TC arm had poor-risk cytogenetics (40.0% vs 34.5%, respectively) and secondary AML (44.6% vs 39.7%, respectively). The response to decitabine was clearly demonstrated in patients with baseline bone marrow blasts \>30% (Figure [2](#F2){ref-type="fig"}). The small subgroup of patients with 20% to 30% blasts (n = 65) demonstrated a significantly better response rate, although notable improvements were not observed in OS \[[@B8]\].

### Baseline cytogenetic risk

Approximately two thirds of patients had intermediate-risk cytogenetics at baseline, including those with a normal karyotype. A trend toward an OS benefit with decitabine treatment was observed in this subgroup \[[@B8]\]. As expected, the subgroup of patients with baseline poor-risk cytogenetics had a shorter median OS \[[@B8]\] and somewhat lower response rates than those in the group with intermediate-risk cytogenetics (Figure [2](#F2){ref-type="fig"}).

### Baseline ECOG performance score

Randomization was stratified for ECOG PS; approximately 74.3% of patients had ECOG PS of 0 or 1. As expected, patients with ECOG PS of 2 showed shorter median OS by treatment arm versus patients with ECOG PS of 0 or 1 \[[@B8]\]. Also as expected, response rates were greater in patients with ECOG PS of 0 or 1 (Figure [2](#F2){ref-type="fig"}). Nevertheless, the subgroup of patients with ECOG PS of 2 showed an OS benefit with decitabine treatment (HR = 0.65; p = 0.025).

### Geographic region

No stratification for geographic region was considered at randomization, thus some imbalance was noted in the number of patients in each treatment arm in some regions. In particular, the Western European subgroup had more patients in the decitabine arm (n = 51) versus the TC arm (n = 34), and the North American/Australian subgroup had fewer patients in the decitabine arm (n = 51) than in the TC arm (n = 69). In the Western European subgroup, OS appeared to differ markedly from the findings in the primary study \[[@B8]\] (Figure [3](#F3){ref-type="fig"}).

![**Overall survival by treatment arm and by geographic region (2010 mature analysis data set). (A)** Decitabine arm; **(B)** Treatment choice \[TC\] arm.](1471-2407-14-69-3){#F3}

Patients from the Western European region in both the decitabine and TC arms received more cycles of therapy than did patients in the other regions. In Western European patients in the TC arm, fewer patients had ECOG PS of 2, poor-risk cytogenetics, or baseline bone marrow count \>50% compared with patients in the decitabine arm. Additionally, more patients in the decitabine arm were aged \>75 years and had poor-risk cytogenetics, baseline bone marrow blast count \>50%, or secondary AML. Unlike other regions, the Western European region showed a markedly increased use of subsequent hypomethylating agents in the TC versus decitabine arm: more than one third of patients (n = 12 \[35%\]) in the TC arm subsequently received treatment with a hypomethylating agent, while only 4 patients (8%) in the decitabine arm were retreated with a hypomethylating agent (including decitabine).

Discussion
==========

Decitabine therapy was previously associated with improved (but nonsignificant) outcomes compared with TC (cytarabine or SC) in older patients with AML \[[@B8]\]. This multivariate analysis of data from a large, randomized phase 3 trial in older patients with newly diagnosed AML demonstrated that all subgroups (age, type of AML, bone marrow blasts, cytogenetic risk, and ECOG PS) had responses favoring decitabine, even those with poorer prognostic factors, such as baseline bone marrow blasts \>30%. Moreover, consistent with known prognostic factors for older patients with AML \[[@B10],[@B11]\], patients aged ≥75 years and 70--74 years had worse prognoses compared with patients \<70 years. Additionally, poorer baseline ECOG PS and disease-related factors, such as poor cytogenetics, higher bone marrow blast counts, low baseline platelet counts, and high WBC counts, all predicted worse OS. Interestingly, neither the type of AML nor patient sex influenced OS.

Despite the association between age and poorer prognosis replicated in these post hoc analyses, the overall trend for treatment benefit with decitabine was more clearly observed in patients aged 70--74 years and in patients ≥75 years compared with those \<70 years. Hazard ratios for OS were 0.79 (p = 0.165) and 0.72 (p = 0.035) for patients aged 70--74 and ≥75 years, respectively \[[@B8]\]. Patients aged \<70 years demonstrated response rates of 16.9% and median OS of 9.1 months \[[@B8]\], which were consistent with overall results for decitabine-treated patients.

Survival and response results in older patients reported in this trial are particularly promising given that published data indicate that response and survival in clinical trials are typically diminished as the patient's age increases. Median survival in this trial was 8.0 months in patients aged 70--74 years and 6.3 months in those aged ≥75 years \[[@B8]\], which compares favorably with historical data in this older population. These favorable findings for decitabine in older patients are intriguing and may warrant further investigation to determine the underlying explanation. A retrospective analysis of 968 adults with AML in 5 Southwest Oncology Group trials revealed a median OS of 6.9 months (95% CI: 5.4--7.7) in patients aged 66--75 years, but only 3.5 months (95% CI: 1.4--6.1) in patients older than 75 years \[[@B12]\]. In a separate analysis of 998 patients aged ≥65 years with AML or high-risk MDS treated with intensive chemotherapy, median OS in patients aged 75 and older was only 18 weeks compared with 34 weeks in patients aged 70--74 years, and 29 weeks in patients aged 65--69 years \[[@B13]\]. In contrast, more recent analyses of azacitidine (n = 55) in patients with 20% to 30% bone marrow blasts versus conventional care (best SC, low-dose cytarabine, or intensive chemotherapy; n = 58) \[[@B14]\], suggest a survival advantage for azacitidine over conventional care of 24.5 months versus 16.0 months (p = 0.005), respectively, although the atypically high median OS associated with conventional care suggests some patient selection bias. In particular, patients in the azacitidine trial had better prognostic factors than did the high-risk patients in the present decitabine trial.

Notable in the current analyses is the outcome for patients in the Western European subgroup, who had a longer median OS compared with patients from other regions. In this small subgroup (n = 85), median OS in the TC arm (12.5 months) for the primary analysis was much longer than that in any other region and was associated with a wide confidence interval. In Western Europe, fewer patients were randomized to the TC arm than to the decitabine arm, which contributed to the greater variability observed in OS curves for the TC arm and to the wide confidence intervals for HRs. In addition, fewer patients in the TC arm had factors associated with poor prognosis compared with those in the decitabine arm. Finally, there was a marked imbalance in subsequent therapy with hypomethylating agents, as more patients in the TC arm than in the decitabine arm received subsequent disease-modifying therapy with a hypomethylating agent. Thus, the OS trend seen in this subgroup might be explained by the combination of the imbalance in baseline characteristics, the high rate of subsequent disease-modifying therapy, and the greater variability of the data owing to the small sample size.

This trial and subsequent analyses had some limitations. To enable a comparison of an IV regimen of decitabine with the standard subcutaneous cytarabine regimen, the trial utilized an open-label study design. Also, sample sizes were small in some subgroups. Nevertheless, decitabine demonstrated robust and fairly consistent results across most defined subgroups in this older population with AML, with a magnitude of effect consistent with that seen in other clinical trials of decitabine, such as the phase 2 trial reported by Cashen and colleagues (median OS, 7.7 months) \[[@B7]\]. The underlying reasons why some subgroups with typically poor prognoses had favorable responses to decitabine are not well understood; further investigation may be warranted to determine the explanations for these findings. The reliability of the results may lend them validity, despite the trial limitations.

Conclusions
===========

Older patients with AML have characteristics that may adversely affect response to conventional therapy. In this multivariate analysis, response to decitabine was associated with known prognostic factors, such as age, ECOG PS, and cytogenetics. Subgroup analyses revealed that response to decitabine compared with that of cytarabine or standard care was most clearly demonstrated in patients aged ≥75 years, a population that is traditionally difficult to treat, with a poor prognosis.
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